semaglutide phase 3 Two Years on Semaglutide phase 3 SUSTAIN trials

The entire selection process is illustrated in the PRISMA flow diagram (Figure 1)

Key findings: Those Who Stayed on the Maximum Tolerated Dose After 60 weeks of weight loss on tirzepatide, people who stayed on the same dose during a maintenance stage (52 weeks) kept off all the weight (about 50 pounds)

Using standardized reconstitution volumes simplifies the math and ensures consistency across the protocol

One common issue that patients encounter after fat is removed is skin laxity

In clinical trials, weekly subcutaneous semaglutide at the 2.4 mg dose (the Wegovy formulation) produced a mean weight loss of approximately 14.9% of body weight over 68 weeks in the STEP 1 trial, compared with 2.4% for placebo

Neither converts neatly into the other